Deployment Positions

**BLACK-WHITE**
Device not yet positioned to deploy. Lockout feature activated.

**BLACK-BLACK**
Deploy, if significantly reduced bleed-back is also seen from bleed-back window.

**BLACK-RED**
Release slight tension on device until window shows BLACK-BLACK. Otherwise switch to manual compression.

---

**Combining clinical safety** and **ease-of-use**, the **Cordis ExoSeal®** Vascular Closure Device means a more confident close and improved patient outcomes.

- Easy-to-Use Functionality
- Trusted Bioabsorbable Technology
- Precise Extravascular Closure
- Excellent Clinical Results*

---

**Cordis ExoSeal®**
Vascular Closure Device

*Maximise Clinical Safety*.  
*Clinical data from the ‘ECLIPSE Trial’ indicates safety in terms of vascular injury, access site-related bleeding, infection or nerve injury, new ipsilateral lower extremity ischemia or SAE.*

---

*Important Information:*
Prior to use, refer to the “Instructions for Use” supplied with these devices for indications, contraindications, side effects, suggested procedure, warnings, and precautions. As part of the Cordis policy of continuous product development, we reserve the right to change product specifications without prior notification. For healthcare professionals only.

© 2017 Cardinal Health. All rights reserved. CORDIS, the Cordis LOGO, and EXOSEAL are trademarks or registered trademarks of Cardinal Health. EU2134 03/17

---

Follow us on:  
CORDIS EM  
LinkedIn page
Secure and Effective - Polyglycolic Acid (PGA) Plug Material
- To securely close the femoral artery puncture site
- While causing a low tissue reactivity to minimize access site complications*
- Fully absorbable within 60 – 90 days
Secure and Precise Extravascular Closure
- Lock-out feature to avoid intravascular deployment
- Deploys Haemostatic plug without impeding arterial blood flow
- Provides two visual signals to increase operator confidence and patient comfort
Easy to Use
- Deployed through existing procedural sheath**
- 2 visual indicators provide precise and secure extravascular arterial closure

Select the appropriate ExoSeal® french size to match your procedural sheath size.**
Insert the ExoSeal® Device into the sheath and advance to the level of the black marker band.

Pull the sheath and the ExoSeal® Device back (retract with left hand, maintain 80°-45° angle with right) – watch bleed-back indicator for a significant reduction in pulsatile flow.

*Clinical data from the ‘ECLIPSE Trial’ indicates safety in terms of vascular injury, access site-related bleeding, infection or nerve injury, new ipsilateral lower extremity ischemia or SAE.

**Compatible with sheaths up to 12 cm. Please consult IFU for further details.

The ExoSeal® Vascular Closure Device is intended for femoral artery puncture site closure, reducing time to haemostasis and ambulation compared to manual compression in patients who have undergone diagnostic or interventional procedures using a standard 5F, 6F, 7F introducer sheath with up to a 12 cm working length.

1. Select the appropriate ExoSeal® french size to match your procedural sheath size.**
2. Insert the ExoSeal® Device into the sheath and advance to the level of the black marker band.
3. Pull the sheath and the ExoSeal® Device back (retract with left hand, maintain 80°-45° angle with right) – watch bleed-back indicator for a significant reduction in pulsatile flow.
4. Retract the sheath back to the wire cowling – check for pulsatile blood flow from the bleed-back indicator.
5. When flow from the bleed-back indicator slows, watch for the indicator window to change to all BLACK, then depress the plug deployment button. See back panel of this brochure for more details on indicator window.
6. Continue to retract the sheath, compressing the green wire cowling against the white handle. Listen for a ‘click’. The sheath is now secured to the ExoSeal® Device and the indicator wire has deployed.
7. Remove the ExoSeal® Device and sheath assembly and apply light fingertip pressure at the puncture site for two minutes. Dress the site per institutional protocol after haemostasis is achieved.